Mounting a targeted strike on unwanted immune responses.
Cohen
J
J
D000069594:Abatacept; D000818:Animals; D000938:Antigen-Presenting Cells / Q000276:immunology*; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000276:immunology*; D060908:CTLA-4 Antigen; D006084:Graft Rejection; D006801:Humans; D018796:Immunoconjugates; D007141:Immunoglobulin Fc Fragments; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D051379:Mice; D008954:Models, Biological; D011948:Receptors, Antigen, T-Cell / Q000187:drug effects / Q000502:physiology*; D011956:Receptors, Cell Surface / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000494:pharmacology; D013601:T-Lymphocytes / Q000276:immunology*; D014181:Transplantation Immunology
D015703:Antigens, CD; D000943:Antigens, Differentiation; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; C556707:Ctla4 protein, mouse; D018796:Immunoconjugates; D007141:Immunoglobulin Fc Fragments; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D011948:Receptors, Antigen, T-Cell; D011956:Receptors, Cell Surface; D011993:Recombinant Fusion Proteins; D000069594:Abatacept